Cannabinoids: effects on vomiting and nausea in animal models

  • Linda A. Parker
  • Cheryl L. Limebeer
  • Magdalena Kwiatkowska
Part of the Milestones in Drug Therapy MDT book series (MDT)


Taste Aversion Smoke Marijuana Anticipatory Nausea Dorsal Vagal Complex Taste Avoidance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Andrews PLR, Davis CJ (1995) The physiology of emesis induced by anti-cancer therapy. In: J Reynolds, PLR Andrews, CJ Davis (eds): Serotonin and the scientific basis ofanti-emetic therapy. Oxford Clinical Communications, Oxford, 25–49Google Scholar
  2. 2.
    Aapro MS, Kirchner V, Terrey JP (1994) The incidence of anticipatory nausea and vomiting after repeat cycle chemotherapy: The effect of granisetron. Br J Cancer 69: 957–960PubMedGoogle Scholar
  3. 3.
    Costall B, Domeney AM, Naylor RJ, Tattersall FD (1986) 5-Hydroxytryptamine receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology 25: 959–961CrossRefPubMedGoogle Scholar
  4. 4.
    Matsuki N, Ueno S, Kaji T, Ishihara A, Wang CH, Saito H (1988) Emesis induced by cancer chemotherapeutic agents in the Suncus murinus: A new experimental model. Jpn Pharmacol 48:303–306Google Scholar
  5. 5.
    Miner WJ, Sanger GJ (1986) Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 88: 497–499PubMedGoogle Scholar
  6. 6.
    Torii Y, Saito H, Matsuki N (1991) Selective blockade of cytotoxic drug-induced emesis by 5-HT3 receptor antagonists in Suncus murinus. Japan J Pharmacol 55: 107–113Google Scholar
  7. 7.
    Ueno S, Matsuki N, Saito H (1987) Suncus murinus: A new experimental model in emesis research. Life Sci 43: 513–518CrossRefGoogle Scholar
  8. 8.
    Aapro MS, Thuerlimann B, Sessa C, De Pree C, Bernhard J, Maibach R; Swiss Group for Clinical Cancer Research (2003) A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Ann Oncol 14: 291–297CrossRefPubMedGoogle Scholar
  9. 9.
    Bartlett N, Koczwara B (2002) Control of nausea and vomiting after chemotherapy: what is the evidence? Int Med J 32: 401–407CrossRefGoogle Scholar
  10. 10.
    Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR (2003) Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-Hydroxytryptamine-3 antiemetics. Cancer 97: 2880–2886CrossRefPubMedGoogle Scholar
  11. 11.
    Schnell, FM (2003) Chemotherapy-induced nausea and vomiting: The importance of acute antiemetic control. Oncologist 8: 187–198CrossRefPubMedGoogle Scholar
  12. 12.
    Reynolds DJM, Barber NA, Grahame-Smith DG, Leslie RA (1991) Cisplatin-evoked induction of c-fos protein in the brainstem of the ferret: The effect of cervical vagotomy and the antiemetic 5HT-3 receptor antagonist granisetron. Brain Res 565: 321–336CrossRefPubMedGoogle Scholar
  13. 13.
    Tsukada H, Hirose T, Yokoyama A, Kurita Y (2001) Randomized comparison of ondansetron plus dexamethasone with dexamethasone alone for control of delayed cisplatin-induced emesis. Eur J Cancer 37: 2398–2404CrossRefPubMedGoogle Scholar
  14. 14.
    Ballatori E, Roila F (2003) Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes 1: 46CrossRefPubMedGoogle Scholar
  15. 15.
    Grelot L, Milano S, LeStunff H (1995) Does 5-HT play a role in the delayed phase of cisplatin-induced emesis? In: J Reynolds, PLR Andrews, CJ Davis (eds): Serotonin and the scientific basis of anti-emetic therapy. Oxford Clinical Communications, Oxford, 181–191Google Scholar
  16. 16.
    Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, Carides AD, Evans JK, Horgan KJ (2003) Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 39:1074–1080CrossRefPubMedGoogle Scholar
  17. 17.
    Rudd J, Jordan CC, Naylor RJ (1996) The action of the NK1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret. Br J Pharmacol 119: 931–936PubMedGoogle Scholar
  18. 18.
    Rudd J, Naylor RJ (1996) An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret. Br JPharmacol 118: 209–214Google Scholar
  19. 19.
    Sam TSW, Cheng JTY, Johnston KD, Kan KKW, Ngan MP, Rudd JA, Wai MK, Yeung JHK (2003) Action of 5-HT3 antagonists and dexamethasone to modify cisplatin-induced emesis in Suncus murinus (house musk shrew). Eur J Pharm 472: 135–145CrossRefGoogle Scholar
  20. 20.
    Morrow GR, Dobkin PL (1988) Anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment: prevalence, etiology and behavioral interventions. Clin Psychol Rev 8:517–556CrossRefGoogle Scholar
  21. 21.
    Nesse RM, Carli T, Curtis GC, Kleinman PD (1980) Pretreatment nausea in cancer chemotherapy: A conditioned response? Psychosom Med 42: 33–36PubMedGoogle Scholar
  22. 22.
    Stockhorst U, Klosterhalfen S, Klosterhalfen W, Winkelmann M, Steingrueber HJ (1993) Anticipatory nausea in cancer patients receiving chemotherapy: Classical conditioning etiology and therapeutical implications. Integr Physiol Behav Sci 28: 177–181PubMedGoogle Scholar
  23. 23.
    Gardner C, Armour DR, Beattie DT, Gale JD, Hawcock AB, Kilpatrick GJ, Twissell DJ, Ward P (1996) GR205171: A novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity. Regul Peptides 65: 45–53CrossRefGoogle Scholar
  24. 24.
    Darmani NA (2001) Delta-9-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 24: 198–203CrossRefPubMedGoogle Scholar
  25. 25.
    Darmani NA (2001) Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB1 receptor in the least shrew. Pharm Biochem Behav 69: 239–249CrossRefGoogle Scholar
  26. 26.
    Darmani NA (2001) The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. Eur J Pharm 430: 49–58CrossRefGoogle Scholar
  27. 27.
    Darmani NA (2002) The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachi-donoylglycerol) are blocked by Delta (9)-tetrahydrocannabinol and other cannabinoids. J Pharmacol Exp Ther 300: 34–42CrossRefPubMedGoogle Scholar
  28. 28.
    Darmani NA, Johnson CJ (2004) Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis. Eur J Pharmacol 488: 201–212CrossRefPubMedGoogle Scholar
  29. 29.
    Darmani NA, Sim-Selley LJ, Martin BR, Janoyan JJ, Crim JL, Parekh B, Breivogel CS (2003) Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation. Eur J Pharmacol 459: 83–95CrossRefPubMedGoogle Scholar
  30. 30.
    McCarthy LE, Borison HL (1981) Anti-emetic activity of N-methyllevonantrobil and naboline in cisplatin treated cats. J Clin Pharmacol 21: 30S–37SPubMedGoogle Scholar
  31. 31.
    Parker LA, Kwiatkowska M, Burton P, Mechoulam R (2003) Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus. Psychopharmacology 171: 156–161CrossRefPubMedGoogle Scholar
  32. 32.
    Kwaitkowska M, Parker LA, Burton P, Mechoulam R (2004) A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology 174: 254–259PubMedGoogle Scholar
  33. 33.
    Simoneau II, Hamza MS, Mata HP, Siegel EM, Vanderah TW, Porreca F, Makryannis A, Malan P (2001) The cannabinoid agonist WIN 55,212-2 suppresses opioid-induced emesis in ferrets. Anesthesiology 94: 882–886CrossRefPubMedGoogle Scholar
  34. 34.
    Van Sickle MD, Oland LD, HO W, Hillard CJ, Mackie K, Davison JS, Sharkey KA (2001) Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 121: 767–774PubMedGoogle Scholar
  35. 35.
    Van Sickle MD, Oland LD, Mackie K, Davison JS, Sharkey KA (2003) Δ9-Tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol 285: G566–G576PubMedGoogle Scholar
  36. 36.
    Limebeer CL, Parker LA (1999) Delta-9-tetrahydrocannabinol interferes with the establishment and the expression of conditioned disgust reactions produced by cyclophosphamide: a rat model of nausea. NeuroRep 26: 371–384Google Scholar
  37. 37.
    Parker L A, Mechoulam R (2003) Cannabinoid agonists and an antagonist modulate conditioned gaping in rats. Integr Physiol Behav Sci 38: 134–146Google Scholar
  38. 38.
    Parker LA, Mechoulam R, Schlievert C (2002) Cannabidiol, a non-psychoactive component of cannabis, and its dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuro Rep 13: 567–570Google Scholar
  39. 39.
    Parker LA, Mechoulam R, Shlievert C, Abbott L, Fudge ML, Burton P (2003) Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacology 166: 156–162PubMedGoogle Scholar
  40. 40.
    Iversen LL (2000) The Science of Marijuana. Oxford University Press, New YorkGoogle Scholar
  41. 41.
    Gaoni Y, Mechoulam R (1964) Isolation, structure and partial synthesis of an active constituent of hashish. JAm Chem Soc 86: 1646–1647CrossRefGoogle Scholar
  42. 42.
    Felder CC, Glass M (1998) Cannabinoid receptors and their endogenous agoinsts. Annu Rev Pharmacol Toxicol 38: 179–200CrossRefPubMedGoogle Scholar
  43. 43.
    Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561–564CrossRefPubMedGoogle Scholar
  44. 44.
    Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor. Mol Pharmacol 34: 605–613PubMedGoogle Scholar
  45. 45.
    Mechoulam R, Ben-Shabat S, Hanug L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83–90CrossRefPubMedGoogle Scholar
  46. 46.
    Deutsch DG, Chin SA (1993) Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46: 791–796CrossRefPubMedGoogle Scholar
  47. 47.
    Pertwee RG (2001) Cannabinoids and the gastrointestinal tract. Gut 48: 859–867CrossRefPubMedGoogle Scholar
  48. 48.
    Himmi T, Dallaporta M, Perrin J, Orsini JC (1996) Neuronal responses to delta9-tetrahyrocannabinol in the solitary tract nucleus. Eur J Pharmacol 312: 273–279CrossRefPubMedGoogle Scholar
  49. 49.
    Himmi T, Perrin J, El Ouazzani T, Orsini JC (1998) Neuronal responses to cannabinoid receptor ligands in the solitary tract nucleus. Eur J Pharmacol 359: 49–54CrossRefPubMedGoogle Scholar
  50. 50.
    Kimura T, Ohta T, Watanabe K, Yoshimura H, Yamamoto I (1998) Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5HT) receptor. Biol Pharm Bull 21: 224–226PubMedGoogle Scholar
  51. 51.
    Hermann H, Marsicano G, Lutz B (2002) Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 109: 451–460CrossRefPubMedGoogle Scholar
  52. 52.
    Barann M, Molderings G, Bruss M, Bonisch H, Urban BW, Gothert M (2002) Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br JPharm 137: 589–596CrossRefGoogle Scholar
  53. 53.
    Fan P (1995) Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. JNeurophysiology 73: 907–910Google Scholar
  54. 54.
    Howlett AC, Barth F, Bonner TI, Cabral P, Casellaa G, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR et al. (2002) International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacol Rev 54: 161–202CrossRefPubMedGoogle Scholar
  55. 55.
    Schlicker E, Kathman M (2001) Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 22: 565–571CrossRefPubMedGoogle Scholar
  56. 56.
    Tramer, MR, Carroll D, Campbell FA, Reynolds DJM, Moore RA, McQuay HJ (2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. Br Med J 323: 1–8Google Scholar
  57. 57.
    Soderpalm AHV, Schuster A, deWit H (2001) Antiemetic efficacy of smoked marijuana: Subjective and behavioral effects on nausea induced by syrup of ipecac. Pharm Biochem Behav 69:343–350CrossRefGoogle Scholar
  58. 58.
    Schwartz RH, Beveridge RA (1994) Marijuana as an antiemetic drug: How useful is it today? Opinions from clinical oncologists. JAddict Dis 13: 53–65Google Scholar
  59. 59.
    Abrahamov A, Abrahamov A, Mechoulam R (1995) An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci 56: 2097–2102CrossRefPubMedGoogle Scholar
  60. 60.
    Grinspoon L, Bakalar JB (1993) Marijuana: the Forbidden Medicine. Yale University Press, New HavenGoogle Scholar
  61. 61.
    Mechoulam R, Parker LA, Gallily R (2002) Cannabidiol: An overview of some pharmacological aspects. J Clin Pharmacol 42: 11S–19SPubMedGoogle Scholar
  62. 62.
    Bisogno T, Hanug L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V (2001) Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134: 845–852CrossRefPubMedGoogle Scholar
  63. 63.
    Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldman M (2000) The non-psychoactive cannabis-constituent cannabidiol is an oral anti-arthritc therapeutic in marine collagen-induced arthritis. Proc Natl Acad Sci USA 97: 9561–9566CrossRefPubMedGoogle Scholar
  64. 64.
    Hampson AJ, Grimaldi M, Axelrod J (1998) Cannabidiol and delta-9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95: 8268–8273CrossRefPubMedGoogle Scholar
  65. 65.
    Feigenbaum JJ, Richmond SA, Weissman Y, Mechoulam R (1989) Inhibition of cisplatin-induced emesis in the pigeon by a non-psychotropic synthetic cannabinoid. Eur J Pharmacol 4: 159–165CrossRefGoogle Scholar
  66. 66.
    Ferrari F, Ottanik A, Giuliani D (1999) Cannabimimetic activity in rats and pigeons of HU-210, a potent antiemetic drug. Pharm Biochem Behav 62: 75–80CrossRefGoogle Scholar
  67. 67.
    Gylys JA, Doran KM, Buyniski PJ (1979) Antagonism of cisplatin induced emesis in the dog. Res Commun Chem Pathol Pharmacol 23: 61–68PubMedGoogle Scholar
  68. 68.
    Shannon HE, Martin WR, Silcox D (1978) Lack of antiemetic effect of Δ9-tetrahydrocannabinol in apomorphine-induced emesis in the dog. Life Sci 23: 49–53CrossRefPubMedGoogle Scholar
  69. 69.
    Smith JE, Friedman MI, Andrews PLR (2002) Conditioned food aversion in Suncus murinus (house musk shrew)—a new model for the study of nausea in a species with an emetic reflex. Physiol Behav 73: 593–598CrossRefGoogle Scholar
  70. 70.
    Ito G, Seki M (1998) Ascending projections from the area postrema and the nucleus of the solitary tract of Suncus murinus: Anterograde tracing study using Phaseolus vulgaris Leucoagglutinin. Okajimas Folia Anat Jpn 75: 9–32PubMedGoogle Scholar
  71. 71.
    Shook JE, Burks TF (1989) Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmacol Exp Ther 249: 444–449PubMedGoogle Scholar
  72. 72.
    Bernstein IL (1985) Learned food aversions in the progression of cancer and its treatment. In: Bravemen, N.S. and Bronstein, P. (eds): Experimental Assessments and Clinical Applications of Conditioned Food Aversions, Ann N Y Acad Sci 365–380Google Scholar
  73. 73.
    Pavlov, IP (1927) Conditioned Reflexes (G.V. Anrep, trans.). Oxford University Press, LondonGoogle Scholar
  74. 74.
    Garcia J, Hankins WG, Rusiniak KW (1974) avioral regulation of the milieu interne in man and rat. Science 185: 824–831PubMedGoogle Scholar
  75. 75.
    Garcia J, Rusiniak KW, Brett LP (1977) Conditioning food-illness aversions in wild animals: Caveant canonici. In: H. Davis, Hurowitz (eds): Operant Pavlovian Interactions. Lawrence Erlbaum, Hillsdale, NJ, 273–316Google Scholar
  76. 76.
    Davey VA, Biederman GB (1998) Conditioned antisickness: Indirect evidence from rats and direct evidence from ferrets that conditioning alleviates drug-induced nausea and emesis. JEP: Animal Behavior Processes 24: 483–491CrossRefGoogle Scholar
  77. 77.
    Parker LA, Kemp S (2001) Tetrahydrocannabinol (THC) interferes with conditioned retching in Suncus murinus: An animal model of anticipatory nausea and vomiting (ANV). NeuroReport 12:749–751CrossRefPubMedGoogle Scholar
  78. 78.
    Blackshaw LA, Grundy D (1993) Effects of 5-hydroxytryptamine (5-HT) on the discharge of vagal mechanoreceptors and motility in the upper gastrointestinal tract of the ferret. JAuton Nerv Syst 45:51–59CrossRefGoogle Scholar
  79. 79.
    Grundy D (1998) Visceral afferents and their modulation in animal models of nausea and vomiting. Paper presented at the International Symposium on Nausea and Vomiting: A Multidisciplinary approach, Tutzing, GermanyGoogle Scholar
  80. 80.
    Hillsley D, Kirkup AJ, Grundy D (1992) Direct and indirect actions of 5-HT on the discharge of mesenteric afferent fibres innervating the rat jejunum. J Physiol 506: 551–561CrossRefGoogle Scholar
  81. 81.
    Davis CJ, Harding RK, Leslie RA, Andrews PLR (1986) The organization of vomiting as a protective reflex. In: CJ Davis, G. Lake-Bakaar, DG Grahame-Smith (eds): Nausea and vomiting: Mechanisms and treatment. Springer-Verlag, Berlin, 65–76Google Scholar
  82. 82.
    Billig I, Yates BJ, Rinaman L (2001) Plasma hormone levels and central c-Fos expression in ferrets after systemic administration of cholecystokinin. Am J Physiol Regulat Integrat Comp Physiol 281: R1243–R1255Google Scholar
  83. 83.
    Borrison HL, Wang SC (1953) Physiology and pharmacology of vomiting. Pharmacol Rev 5:193–230PubMedGoogle Scholar
  84. 84.
    Parker LA (1982) Nonconsummatory and consummatory behavioral CRs elicited by lithium-paired and amphetamine-paired flavors. Learn Motiv 13: 281–303CrossRefGoogle Scholar
  85. 85.
    Parker LA (1995) Rewarding drugs produce taste avoidance, but not taste aversion. Neurosci Biobehav Rev 19: 143–151CrossRefPubMedGoogle Scholar
  86. 86.
    Parker LA (1998) Emetic drugs produce conditioned rejection reactions in the taste reactivity test. J Psychophysiol 12: 3–13Google Scholar
  87. 87.
    Parker LA (2003) Taste avoidance and taste aversion: Evidence for two different processes. Learn Behav 31: 165–172PubMedGoogle Scholar
  88. 88.
    Limebeer CL, Parker LA (2000) Ondansetron interferes with the establishment and the expression of conditioned disgust reactions: A rat model of nausea. JEP: Anim Behav Proc 26: 371–384CrossRefGoogle Scholar
  89. 89.
    Limebeer CL, Parker LA (2003) The 5-HT1A agonist 8-OH-DPAT dose-dependently interferes with the establishment and the expression of lithium-induced conditioned rejection reactions in rats. Psychopharmacology 166: 120–126PubMedGoogle Scholar
  90. 90.
    Grill HC, Norgren R (1978) The taste reactivity test. I. Mimetic responses to gustatory stimuli in neurologically normal rats. Brain Res 143: 263–279CrossRefPubMedGoogle Scholar
  91. 91.
    Hunt T, Amit Z (1987) Conditioned taste aversion induced by self-administered drugs: Paradox revisited. Neurosci Biobehav Rev 11: 107–130PubMedGoogle Scholar
  92. 92.
    Reicher MA, Holman EW (1977) Location preference and flavour aversion reinforced by amphetamine in rats. Anim Learn Behav 5: 343–346Google Scholar
  93. 93.
    Pelchat ML, Grill HJ, Rozin P, Jacobs J (1983) Quality of acquired responses to tastes by Rattus norvegicus depends on type of associated discomfort. J Comp Psychol 97: 140–153CrossRefPubMedGoogle Scholar
  94. 94.
    Cromwell HC, Berridge KC (1993) Where does damage lead to enhanced food aversion: The ventral pallidum/substantia innominata or lateral hypothalamus? Br Res 624: 1–110CrossRefGoogle Scholar
  95. 95.
    Zalaquett C, Parker LA (1989) Further evidence that CTAs produced by lithium and amphetamine are qualitatively different. Learn Motiv 20: 413–427CrossRefGoogle Scholar
  96. 96.
    Gamzu E (1977) The multifaceted nature of taste aversion inducing agents: Is there a single common factor? In: L Barker, M Domjan, M Best (eds): Learning mechanisms of food selection. Baylor University Press, Waco, TX, 447–511Google Scholar
  97. 97.
    Parker LA, Corrick ML, Limebeer CL, Kwiatkowska M (2002) Amphetamine and morphine produce a conditioned taste and place preference in the house musk shrew (Suncus murinus). JEP: Anim Behav Proc 28: 75–82CrossRefGoogle Scholar
  98. 98.
    Schaff GE, Theiele TE, Bernstein IL (1998) Conditioning method dramatically alters the role of amygdala in taste aversion learning. Learn Memory 5: 481–492Google Scholar
  99. 99.
    Limebeer CL, Parker, LA and Fletcher, P (2005) Dorsal and Median Raphe lesions potentiate lithium-induced conditioned gaping in rats. Behav Neurosci; in pressGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2005

Authors and Affiliations

  • Linda A. Parker
    • Cheryl L. Limebeer
      • Magdalena Kwiatkowska
        • 1
      1. 1.Department of PsychologyWilfrid Laurier UniversityWaterlooCanada

      Personalised recommendations